Maintaining Investments in New Innovation Act

S 476, the *Maintaining Investments in New Innovation Act*, extends patent exclusivity for certain advanced drug products from 7 to 11 years. It directly affects drug manufacturers developing therapies using genetically targeted technology, such as those that modulate gene function. The bill amends the Social Security Act to define "advanced drug product" as a drug utilizing genetically targeted technology (e.g., gene modulation), qualifying for the longer 11-year market protection period. This change aims to incentivize investment in innovative genetic therapies by providing extended exclusivity.